Lannett Kicks Off Insulin Glargine Trial

Firm Eyes 2023 Filing And 2024 Launch For US Interchangeable Biosimilar Lantus Rival

 
• By Dave Wallace

Lannett has delivered on its promise of kicking off a pivotal clinical trial for its proposed interchangeable biosimilar rival to Lantus by the end of March, as it eyes a 2023 filing and 2024 launch in the US for the insulin glargine product on which it has partnered with HEC.

Road years 2022 2023 2024
The road to an insulin glargine launch stretches to 2024 for Lannett • Source: thodsapol thongdeekhieo / Alamy Stock Photo

More from Biosimilars

More from Products